These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 26645407)

  • 1. Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer.
    Quartino AL; Hillenbach C; Li J; Li H; Wada RD; Visich J; Li C; Heinzmann D; Jin JY; Lum BL
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):77-88. PubMed ID: 26645407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
    Wang B; Deng R; Hennig S; Badovinac Crnjevic T; Kaewphluk M; Kågedal M; Quartino AL; Girish S; Li C; Kirschbrown WP
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):499-512. PubMed ID: 34106303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study.
    Jackisch C; Kim SB; Semiglazov V; Melichar B; Pivot X; Hillenbach C; Stroyakovskiy D; Lum BL; Elliott R; Weber HA; Ismael G
    Ann Oncol; 2015 Feb; 26(2):320-5. PubMed ID: 25403587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.
    Quartino AL; Li H; Jin JY; Wada DR; Benyunes MC; McNally V; Viganò L; Nijem I; Lum BL; Garg A
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):353-361. PubMed ID: 28074265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
    Gligorov J; Ataseven B; Verrill M; De Laurentiis M; Jung KH; Azim HA; Al-Sakaff N; Lauer S; Shing M; Pivot X;
    Eur J Cancer; 2017 Sep; 82():237-246. PubMed ID: 28625777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
    Chen X; Li C; Ewesuedo R; Yin D
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin
    Quartino AL; Li H; Kirschbrown WP; Mangat R; Wada DR; Garg A; Jin JY; Lum B
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):329-340. PubMed ID: 30467591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC).
    Chen SC; Kagedal M; Gao Y; Wang B; Harle-Yge ML; Girish S; Jin J; Li C
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1147-1159. PubMed ID: 29043411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
    Ismael G; Hegg R; Muehlbauer S; Heinzmann D; Lum B; Kim SB; Pienkowski T; Lichinitser M; Semiglazov V; Melichar B; Jackisch C
    Lancet Oncol; 2012 Sep; 13(9):869-78. PubMed ID: 22884505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study.
    Jung KH; Ataseven B; Verrill M; Pivot X; De Laurentiis M; Al-Sakaff N; Lauer S; Shing M; Gligorov J; Azim HA
    Oncologist; 2018 Oct; 23(10):1137-1143. PubMed ID: 30018134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review.
    Kolberg HC; Jackisch C; Hurvitz SA; Winstone J; Barham H; Hanes V; Courmier D
    Breast; 2021 Jun; 57():95-103. PubMed ID: 33799233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer.
    Bruno R; Washington CB; Lu JF; Lieberman G; Banken L; Klein P
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):361-9. PubMed ID: 15868146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.
    De Cock E; Pivot X; Hauser N; Verma S; Kritikou P; Millar D; Knoop A
    Cancer Med; 2016 Mar; 5(3):389-97. PubMed ID: 26806010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.
    Pivot X; Gligorov J; Müller V; Barrett-Lee P; Verma S; Knoop A; Curigliano G; Semiglazov V; López-Vivanco G; Jenkins V; Scotto N; Osborne S; Fallowfield L;
    Lancet Oncol; 2013 Sep; 14(10):962-70. PubMed ID: 23965225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of Trastuzumab After Subcutaneous and Intravenous Administration in Obese Patients.
    González García J; Gutiérrez Nicolás F; Ramos Díaz R; Nazco Casariego GJ; Viña Romero MM; Llabres Martinez M; Llanos Muñoz M; Batista López JN; Jiménez Sosa A; Ceballos Lenza I; Cruz Jurado J
    Ann Pharmacother; 2020 Aug; 54(8):775-779. PubMed ID: 31971005
    [No Abstract]   [Full Text] [Related]  

  • 16. Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial.
    Gligorov J; Curigliano G; Müller V; Knoop A; Jenkins V; Verma S; Osborne S; Lauer S; Machackova Z; Fallowfield L; Pivot X
    Breast; 2017 Aug; 34():89-95. PubMed ID: 28549309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
    Yapa SW; Roth D; Gordon D; Struemper H
    Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.
    Garg A; Quartino A; Li J; Jin J; Wada DR; Li H; Cortés J; McNally V; Ross G; Visich J; Lum B
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):819-29. PubMed ID: 25119184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated.
    Leyland-Jones B; Colomer R; Trudeau ME; Wardley A; Latreille J; Cameron D; Cubedo R; Al-Sakaff N; Feyereislova A; Catalani O; Fukushima Y; Brewster M; Cortés J
    J Clin Oncol; 2010 Feb; 28(6):960-6. PubMed ID: 20026806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer.
    Bernadou G; Campone M; Merlin JL; Gouilleux-Gruart V; Bachelot T; Lokiec F; Rezai K; Arnedos M; Diéras V; Jimenez M; Paintaud G; Ternant D
    Br J Clin Pharmacol; 2016 May; 81(5):941-8. PubMed ID: 26714164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.